FDA slaps down Alk­er­mes for mis­lead­ing Viv­it­rol ads — don't for­get vul­ner­a­bil­i­ty to opi­oid over­dose

2 hours ago
Regulatory

FDA in-house re­view spot­lights an is­sue with one of Hori­zon's end­points but notes ef­fi­ca­cy for lead drug

7 hours ago
R&D

Seat­tle Ge­net­ics de­tails pos­i­tive OS and PFS da­ta for tu­ca­tinib in breast can­cer

7 hours ago
R&D

Ste­fan Fraenkel takes over as chief of In­cep­tua Group; Christi Shaw has a plan to make Yescar­ta safer

7 hours ago
Protocols

Bat­tered, cash hun­gry In­tec feels the burn of No­var­tis re­jec­tion

8 hours ago
Deals

What does $6.9B buy these days in on­col­o­gy R&D? As­traZeneca has a land­mark an­swer

8 hours ago
R&D

Bris­tol-My­ers shows off a low-pro­file AML con­tender it gained from Cel­gene buy­out — and they’re tak­ing it straight to the FDA

8 hours ago
R&D

De­sert­ed by Astel­las and Mer­ck, lit­tle Cor­re­vio still can't win over FDA pan­el con­cerned with its AFib drug's safe­ty

9 hours ago
R&D

New trade deal knocks out long-sought bi­o­log­ics pro­tec­tions for drug­mak­ers

11 hours ago
R&D

With loom­ing su­per­bug cri­sis, Iterum miss­es in a key an­tibi­ot­ic tri­al — and its shares tum­ble

11 hours ago
R&D

UP­DAT­ED: Lit­tle Leo Phar­ma en­ters the prize-fight ring with pos­i­tive PhI­II atopic der­mati­tis da­ta. Now they just have to beat Dupix­ent

11 hours ago
R&D

Af­ter sev­er­al high pro­file start­up launch­es, om­niv­o­rous Omega Funds clos­es $438M fund to pur­sue more deals

12 hours ago
Venture

For­eign drug in­spec­tions de­cline as FDA hir­ing strug­gles con­tin­ue

12 hours ago
Regulatory

Am­gen puts its foot down in shiny new South San Fran­cis­co hub as it re­or­ga­nizes R&D ops

Yesterday
Pharma
R&D

As­traZeneca teams up with Deep Mat­ter for AI drug de­vel­op­ment; Can­cer biotech Im­munOs rais­es $15M

Yesterday
Protocols

Ab­b­Vie, Scripps ex­pand part­ner­ship, for­ti­fy fo­cus on can­cer drugs

Yesterday
Deals
R&D

Paul Hud­son promis­es a bright new fu­ture at Sanofi, kick­ing loose me-too drugs and fo­cus­ing on land­mark ad­vances. But can he de­liv­er?

Yesterday
R&D

South Ko­rea jails 3 Sam­sung ex­ecs for de­stroy­ing ev­i­dence in Bi­o­Log­ics probe

Yesterday
People
Regulatory

Cel­lar­i­ty, Flag­ship's $50M bet on net­work bi­ol­o­gy, mar­ries ma­chine learn­ing and sin­gle-cell tech for drug dis­cov­ery

Yesterday
Startups

Sanofi’s big week in­cludes a promis­ing PhI­II for an or­phan dis­ease drug, with plans for a pitch to the FDA

Yesterday
R&D

In­scrip­ta push­es fund­ing to $260 mil­lion as they launch genome edit­ing plat­form

Yesterday
R&D

Re­pub­li­cans un­veil a drug price bill to ri­val the De­moc­rats — promis­ing low­er prices and more cures

Yesterday
Pharma

Per­cep­tive teams up with Chris Garabe­di­an to open up a new, $210M biotech fund fo­cused on A rounds

Yesterday
Startups
Venture

US biosim­i­lar launch­es about to turn a cor­ner

Yesterday
Pharma
1234 Next page Last page